Compare Inovio Pharmaceuticals Inc (INO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Payoneer Global Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Payoneer Global Inc is far larger — about 30.6× Inovio Pharmaceuticals Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PAYO | |
|---|---|---|
Market Cap | $78.55M | $2.40B |
Sector | Health | Technology |
52-Week High | $2.87 | $7.17 |
52-Week Low | $0.66 | $4.27 |
Enterprise Value | $49.56M | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Payoneer (PAYO) trades at $7.07, down 0.28% on the day, with a bullish technical signal from moving averages and an oversold RSI. Revenue grew to $821.16M in 2025, but net income fell to $73.19M, and Q2 2026 earnings missed estimates. The company is set to be acquired by Nuvei for $7.40 per share, pending shareholder approval, amid legal scrutiny over deal fairness.
The outlook is acquisition-driven, with upside limited to the $7.40 buyout price unless a higher bid emerges. Risks include integration challenges, earnings volatility, and legal disputes. Analysts maintain a buy consensus with an $8.20 target, suggesting potential gains if the deal proceeds smoothly, but caution is warranted due to recent profit margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
